Webinar Understanding the Impact of Blockchain on Pharmaceutical Serialization and Track & Trace Requirements

Blockchain technology has the potential to greatly revolutionize many areas of our lives, including improving visibility into pharma value chains. Countries around the world have mandated that pharma products be serialized and tracked/traced through the full supply chain. One important aspect of the U.S. Food and Drug Administration’s (FDA) traceab ility legislation, the Drug Supply Chain Safety Act (DSCSA), is a requirement that by 2023, all prescription drugs be tracked and traced through the supply chain using an interoperable system. While existing serialization and traceability solutions meet the current DSCSA regulations, there is no system in place that is fully interoperable at this time.

The FDA is looking to the pharma industry to develop its own solution for complete interoperability. There is currently work underway to demonstrate the viability of various blockchain solutions for pharma supply chains that has broad participation from the pharma industry, solution providers and regulatory agencies.

The goal of this webinar is to get you up to speed on that work, as well as share how one global technology company envisions developing blockchain solutions for the pharma industry in the near future.

During this webinar, Bob will provide an update for people who aren’t able to be part of the April 30 – May 1 in-person meetings where teams will perform walkthroughs of their work studies. This webinar will also be helpful to those who attended that event and want a summary or refresher on what ground was covered and what will likely take place next. Jean-Pierre Allard will outline the company’s vision and its core development beliefs for blockchain technology; namely, that future blockchain solutions should be industry-specific and vendor-agnostic. He will share the company’s overarching compatibility goals that aim to support blockchain efforts industry-wide, as well as provide insights into how OPTEL hopes to offer integration points and expanded services to all blockchains so that one blockchain can be adopted by the entire pharmaceutical industry.

 

What will you learn: 

  • An overview of the FDA’s Drug Supply Chain Safety Act (DSCSA)
  • How blockchain can be incorporated into serialization and traceability efforts
  • A global technology company’s perspective on blockchain and pharmaceutical serialization

 

Meet our speakers: 

Bob Celeste, Founder, Center for Supply Chain Studies 

Bob Celeste
Bob Celeste has over 30 years of experience in the chemical, financial, pharmaceutical, medical device and retail industries with a focus on business process re-engineering, information management, standards development and usage. For the past 13 years, Bob was senior director, Healthcare with GS1, EPCglobal and GS1 US where he concentrated on working with regulators (FDA, DEA, California, Florida and Nevada Boards of Pharmacy) on the proper use of master data management and track and trace information and practice. The Center for Supply Chain Studies (www.C4SCS.org) is a nonprofit organization, created as a neutral place for group-funded projects to occur and to publish the white papers, reference models and educational material that result from those studies.

 

Jean-Pierre (JP) Allard, Chief Technology Officer, OPTEL GROUP 

Jean-Pierre-Allard-Chief-Technology-Officer_Optel-Group-729x1024
Jean-Pierre’s nearly 20 years’ experience in vision and electronics and a decade-long focus on the pharmaceutical industry have made him a recognized expert in global serialization. A founding member of the Open Serialization Communication Standard, JP is currently chief technology officer for OPTEL, where his main role is to lead the company’s general technological direction. He holds a bachelor’s degree in electrical and electronics engineering from the University of Sherbrooke in Quebec, Canada

Register for the webinar here! 

Share this page